-
Cost-effectiveness of measles control during elimination in Ontario, Canada, 2015
-
View Affiliations Hide AffiliationsLauren Ramsaylauren.ramsay theta.utoronto.ca
-
View Citation Hide Citation
Citation style for this article: . Cost-effectiveness of measles control during elimination in Ontario, Canada, 2015. Euro Surveill. 2019;24(11):pii=1800370. https://doi.org/10.2807/1560-7917.ES.2019.24.11.1800370 Received: 04 Jul 2018; Accepted: 19 Dec 2018
- Previous Article
- Table of Contents
- Next Article
Abstract
Given that measles is eliminated in Canada and measles immunisation coverage in Ontario is high, it has been questioned whether Ontario’s measles outbreak response is worthwhile.
Our objective was to determine cost-effectiveness of measles containment protocols in Ontario from the healthcare payer perspective.
We developed a decision-analysis model comparing Ontario’s measles containment strategy (based on actual 2015 outbreak data) with a hypothetical ‘modified response’. The modified scenario assumed 10% response costs with reduced case and contact tracing and no outbreak-associated vaccinations; it was based on local and provincial administrative and laboratory data and parameters from peer-reviewed literature. Short- and long-term health outcomes, quality-adjusted life years (QALYs) and costs discounted at 1.5%, were estimated. We conducted one- and two-way sensitivity analyses.
The 2015 outbreak in Ontario comprised 16 measles cases and an estimated 3,369 contacts. Predictive modelling suggested that the outbreak response prevented 16 outbreak-associated cases at a cost of CAD 1,213,491 (EUR 861,579). The incremental cost-effectiveness ratio was CAD 739,063 (EUR 524,735) per QALY gained for the outbreak response vs modified response. To meet the commonly accepted cost-effectiveness threshold of CAD 50,000 (EUR 35,500) per QALY gained, the outbreak response would have to prevent 94 measles cases. In sensitivity analyses, the findings were robust.
Ontario’s measles outbreak response exceeds generally accepted cost-effectiveness thresholds and may not be the most efficient use of public health resources from a healthcare payer perspective. These findings should be balanced against benefits of increased vaccine coverage and maintaining elimination status.
Full text loading...